Vertex’s quest for a breakthrough in Type 1 diabetes

Vertex Pharmaceuticals’ CRISPR-based therapy made history as the first drug of its type, transforming care options for sickle ...

Spotlight on Vertex Pharmaceuticals: Analyzing the Surge in Options Activity

Looking at options history for Vertex Pharmaceuticals (NASDAQ: VRTX) we detected 10 trades. If we consider the specifics of ...
Hosted on MSN

Scientists May Have Found a Cure for Diabetes—Here’s What to Know

A new experimental treatment may be able to cure type 1 diabetes. About 83% of the patients were able to stop using insulin after the treatment. Research into the treatment is ongoing. Experts explain ...
Agence France-Presse

Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Transfusion-Dependent Beta Thalassemia and Sickle Cell Disease in Italy

Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with the Italian Medicines Agency (AIFA) for eligible transfusion-dependent beta thalassemia (TDT) and severe sickle ...

Assessing Vertex Pharmaceuticals: Insights From 15 Financial Analysts

Ratings for Vertex Pharmaceuticals (NASDAQ: VRTX) were provided by 15 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.

Three scientists who revolutionized cystic fibrosis treatment win prestigious Lasker award

Their research led to the development of a drug that nearly doubles the life expectancy for adult cystic fibrosis patients.